# **HOWREY & SIMON**

GAU 1634

Attorneys at Law 1299 Pennsylvania Ave., NW Washington, DC 20004-2402 (202) 783-0800 FAX (202) 383-6610

October 13, 1998

Assistant Commissioner of atents Washington, DC 20231

Re:

U.S. Utility Patent Application

Appl., No. 08/971,344; Filed: November 17, 1997

For: Single Nucleotide Polymorphisms And Their Use In Genetic Analysis

Inventor(s): P. Goelet, et al. Our Ref: 04990.0008-2

Sir:

Transmitted herewith for appropriate action by the U.S. Patent and Trademark Office (PTO) are the following documents:

- 1. PTO Form 1083 (duplicate);
- 2. Amendment;
- 3. Petition of Extension of Time (duplicate);
- 4. Associate Power of Attorney;
- 5. Howrey & Simon Check 166710 in the amount of \$475.00;
- 6. Return Postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 08-3038. A duplicate copy of this letter is enclosed.

Respectfully submitted,

Kevin W. McCabe (Reg. No. 41,182)

Silicon Valley

Washington, DC

Los Angeles

## **HOWREY & SIMON**

#### Box No. 34

1299 Pennsylvania Avenue, N.W. Washington, D.C. 20004-2402 (202) 783-0800

FORM PTO-1083

In re Application of: Goelet, P., et al.

Appl. No.: 08/971,344

Filed: November 17, 1997

OT 1 3 1998 7

Attorney Docket No. <u>04990.0008-2</u>

For: Single Nucleotide Polymorphisms and Their use in Genetic Analysis

THE ASSISTANT COMMISSIONER FOR PATENTS

Washington, D.C. 20231

Sir:

Transmitted herewith is an amendment in the above-identified application.

- Small entity status of this application under 37CFR 1.9 and 1.27 has been established by a statement previously submitted;
- A statement to establish small entity status under 37 CFR 1.9 and 1.27 is enclosed;
- The claim fee has been calculated as shown below:

| (Col. 1) |   |                                  |       |                                       | (Col. 2) |                  | (Col. 3) |  |
|----------|---|----------------------------------|-------|---------------------------------------|----------|------------------|----------|--|
|          | R | Claims Remaining After Amendment |       | Highest No.<br>Previously<br>Paid For |          | Present<br>Extra |          |  |
| TOTAL    | * | 13                               | MINUS | **                                    | 31       | =                | 0        |  |
| INDEP.   | * | 3                                | MINUS | **                                    | 9        | =                | 0        |  |
|          | L | 3<br>ON OF MULTIPLE              |       | **                                    | 9        | <u> </u>         | 0        |  |

| SMALL ENTITY        |               |       |  |  |  |
|---------------------|---------------|-------|--|--|--|
| Rate                | Addit.<br>Fee |       |  |  |  |
| x 11 =              | \$            | 00.00 |  |  |  |
| x 41 =              | \$            | 00.00 |  |  |  |
| +135 =              | \$            | 00,00 |  |  |  |
| Total<br>Addit. Fee | \$            | 00.00 |  |  |  |

| OTHER THAN A<br>SMALL ENTITY |               |       |  |  |  |  |  |
|------------------------------|---------------|-------|--|--|--|--|--|
| Rate                         | Addit.<br>Fee |       |  |  |  |  |  |
| x 22 =                       | \$_           | 00.00 |  |  |  |  |  |
| x 82 =                       | \$            | 00.00 |  |  |  |  |  |
| + 270 =                      | \$            | 00.00 |  |  |  |  |  |
| TOTAL                        | \$            | 00.00 |  |  |  |  |  |

- \* If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.
- \*\* If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, write "20" in this space.
- \*\*\* If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, write "3" in this space.

  The "Highest Number Previously Paid For" (Total or Independent) is the highest number found from the equivalent box in Col. 1 of a prior amendment or the number of claims originally filed.

Please charge my Deposit Account No. <u>08-3038</u> in the amount of \$\_\_\_\_. A duplicate copy of this sheet is attached.

- $\underline{xx}$  A check in the amount of \$475.00 is attached for the Petition of Extension of Time Fee.
- The U.S. Patent and Trademark Office is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. <u>08-3038</u>. A duplicate copy of this sheet is attached.
  - xx Any filing fees under 37 CFR 1.16 for the presentation of extra claims.
  - xx Any patent application processing fees under 37 CFR 1.17.

Date 13 5x 7. 1992

Kevin W. McCabe (Regis. No. 41,182)

Or

OR

# PATENT IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: **P. GOELET ET AL.** 

Serial No: 08/971,344

Filed: November 17, 1997

OT 1 3 1998 3

Atty.Dkt.: 04990.0008-2

Examiner: B. Sisson

Art Unit: 1634

For: SINGLE NUCLEOTIDE

POLYMORPHISMS AND THEIR USE IN GENETIC ANALYSIS

### **AMENDMENTS AND REMARKS**

Assistant Commissioner of Patents and Trademarks Washington, DC 20231

Sir:

In response to the Official Office Action of April 14, 1998, issued with respect to the above-identified application, Applicants herewith submit the following Amendments and Remarks and Petition for Three Month Extension of Time, extending the period of response from July 14, 1998 to October 14, 1998.

## **AMENDMENTS**

#### IN THE SPECIFICATION:

On page 31, line 3, please replace the term "Tween-20" with the term -- polyoxyethylenesorbitan-20 (TWEEN-20)

On page 31, line 13, please replace the term "Tween-20" with the term -- TWEEN-20 --.

## IN THE CLAIMS:

Please amend claim 47 as follows:

47 [Amended]. A method for analyzing DNA of a target human by identifying at least two single nucleotide polymorphic sites, wherein said method comprises:

(A) selecting said at least two single nucleotide polymorphic sites for such analysis;

<u>G'</u>